The current status of the use of palonosetron (Q51245760)

2 April 2018

editorial

0 references

title

The current status of the use of palonosetron (English)

1 reference

2 April 2018

author name string

Rudolph Navari

series ordinal

1 reference

2 April 2018

language of work or name

English

0 references

publication date

7 May 2013

1 reference

2 April 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

2 April 2018

volume

1 reference

2 April 2018

issue

1 reference

2 April 2018

page(s)

1281-1284

1 reference

2 April 2018

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Aprepitant: a review of its use in the prevention of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemothe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.799141

10.1517/14656566.2013.799141

21 January 2018

Identifiers

DOI

1 reference

2 April 2018

release_325leqdqzzep5av7dgkopp6apa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/325leqdqzzep5av7dgkopp6apa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

2 April 2018